Evidence map›Paper›PMID 37854458›Full record

ArticleThe Lancet regional health. Western Pacific2023

Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study.

Bette Liu, Sandrine Stepien, Timothy Dobbins, Heather Gidding, David Henry, Rosemary Korda, Lucas Mills, Sallie-Anne Pearson, Nicole Pratt, Claire M Vajdic and 2 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Bette LiuNational Centre for Immunisation Research and Surveillance, Australia.
Sandrine StepienNational Centre for Immunisation Research and Surveillance, Australia.
Timothy DobbinsSchool of Population Health, UNSW Sydney, Australia.
Heather GiddingNational Centre for Immunisation Research and Surveillance, Australia.
David HenrySchool of Population Health, UNSW Sydney, Australia.
Rosemary KordaNational Centre for Epidemiology and Population Health, Australian National University, Australia.
Lucas MillsDepartment of Health and Aged Care, Commonwealth Government of Australia, Australia.
Sallie-Anne PearsonSchool of Population Health, UNSW Sydney, Australia.
Nicole PrattNHMRC Medicines Intelligence Centre of Research Excellence, Australia.
Claire M VajdicNHMRC Medicines Intelligence Centre of Research Excellence, Australia.
Jennifer WelshNational Centre for Epidemiology and Population Health, Australian National University, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Australia.
UNSW Sydney · AUAustralian National University · AUThe University of Sydney · AUAustralian Government · AUBond University · AUNational Centre for Immunisation Research & Surveillance · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022. Methods: We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates. Findings: From January-May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June-November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50-62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June-November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56-59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16-22%). Interpretations: COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk. Funding: This study was funded by the Health Economics Research Division in the Australian Government Department of Health and Aged Care.

Indexed as

COVID-19MortalityVaccine effectivenessWaning effectiveness

Identifiers

PMID37854458
PMCPMC10579525
OpenAlexW4387425581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.